-
Something wrong with this record ?
Synthesis and Cytotoxic Activity of Triterpenoid Thiazoles Derived from Allobetulin, Methyl Betulonate, Methyl Oleanonate, and Oleanonic Acid
L. Borkova, R. Adamek, P. Kalina, P. Drašar, P. Dzubak, S. Gurska, J. Rehulka, M. Hajduch, M. Urban, J. Sarek,
Language English Country Germany
Document type Journal Article
- MeSH
- Apoptosis drug effects MeSH
- G2 Phase Cell Cycle Checkpoints drug effects MeSH
- M Phase Cell Cycle Checkpoints drug effects MeSH
- Oleanolic Acid analogs & derivatives chemistry MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents chemical synthesis chemistry toxicity MeSH
- Drug Screening Assays, Antitumor MeSH
- Thiazoles chemical synthesis chemistry toxicity MeSH
- Triterpenes chemistry MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
A total of 41 new triterpenoids were prepared from allobetulone, methyl betulonate, methyl oleanonate, and oleanonic acid to study their influence on cancer cells. Each 3-oxotriterpene was brominated at C2 and substituted with thiocyanate; subsequent cyclization with the appropriate ammonium salts gave N-substituted thiazoles. All compounds were tested for their in vitro cytotoxic activity on eight cancer cell lines and two non-cancer fibroblasts. 2-Bromoallobetulone (2 b) methyl 2-bromobetulonate (3 b), 2-bromooleanonic acid (5 b), and 2-thiocyanooleanonic acid (5 c) were best, with IC50 values less than 10 μm against CCRF-CEM cells (e.g., 3 b: IC50 =2.9 μm) as well as 2'-(diethylamino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 f, IC50 =9.7 μm) and 2'-(N-methylpiperazino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 k, IC50 =11.4 μm). Compound 5 c leads to the accumulation of cells in the G2 phase of the cell cycle and inhibits RNA and DNA synthesis significantly at 1×IC50 . The G2 /M cell-cycle arrest probably corresponds to the inhibition of DNA/RNA synthesis, similar to the mechanism of action of actinomycin D. Compound 5 c is new, active, and nontoxic; it is therefore the most promising compound in this series for future drug development. Methyl 2-bromobetulonate (3 b) and methyl 2-thiocyanometulonate (3 c) were found to inhibit nucleic acid synthesis only at 5×IC50 . We assume that in 3 b and 3 c (unlike in 5 c), DNA/RNA inhibition is a nonspecific event, and an unknown primary cytotoxic target is activated at 1×IC50 or lower concentration.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023363
- 003
- CZ-PrNML
- 005
- 20200728083835.0
- 007
- ta
- 008
- 170720s2017 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cmdc.201600626 $2 doi
- 035 __
- $a (PubMed)28084676
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Borkova, Lucie $u Department of Organic Chemistry, Faculty of Science, Palacky University in Olomouc, 17. listopadu 1192/12, 771 46, Olomouc, Czech Republic.
- 245 10
- $a Synthesis and Cytotoxic Activity of Triterpenoid Thiazoles Derived from Allobetulin, Methyl Betulonate, Methyl Oleanonate, and Oleanonic Acid / $c L. Borkova, R. Adamek, P. Kalina, P. Drašar, P. Dzubak, S. Gurska, J. Rehulka, M. Hajduch, M. Urban, J. Sarek,
- 520 9_
- $a A total of 41 new triterpenoids were prepared from allobetulone, methyl betulonate, methyl oleanonate, and oleanonic acid to study their influence on cancer cells. Each 3-oxotriterpene was brominated at C2 and substituted with thiocyanate; subsequent cyclization with the appropriate ammonium salts gave N-substituted thiazoles. All compounds were tested for their in vitro cytotoxic activity on eight cancer cell lines and two non-cancer fibroblasts. 2-Bromoallobetulone (2 b) methyl 2-bromobetulonate (3 b), 2-bromooleanonic acid (5 b), and 2-thiocyanooleanonic acid (5 c) were best, with IC50 values less than 10 μm against CCRF-CEM cells (e.g., 3 b: IC50 =2.9 μm) as well as 2'-(diethylamino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 f, IC50 =9.7 μm) and 2'-(N-methylpiperazino)olean-12(13)-eno[2,3-d]thiazole-28-oic acid (5 k, IC50 =11.4 μm). Compound 5 c leads to the accumulation of cells in the G2 phase of the cell cycle and inhibits RNA and DNA synthesis significantly at 1×IC50 . The G2 /M cell-cycle arrest probably corresponds to the inhibition of DNA/RNA synthesis, similar to the mechanism of action of actinomycin D. Compound 5 c is new, active, and nontoxic; it is therefore the most promising compound in this series for future drug development. Methyl 2-bromobetulonate (3 b) and methyl 2-thiocyanometulonate (3 c) were found to inhibit nucleic acid synthesis only at 5×IC50 . We assume that in 3 b and 3 c (unlike in 5 c), DNA/RNA inhibition is a nonspecific event, and an unknown primary cytotoxic target is activated at 1×IC50 or lower concentration.
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x toxicita $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a kontrolní body fáze G2 buněčného cyklu $x účinky léků $7 D059565
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kontrolní body M fáze buněčného cyklu $x účinky léků $7 D059566
- 650 _2
- $a kyselina olenalová $x analogy a deriváty $x chemie $7 D009828
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a thiazoly $x chemická syntéza $x chemie $x toxicita $7 D013844
- 650 _2
- $a triterpeny $x chemie $7 D014315
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Adamek, Richard $u Department of Organic Chemistry, Faculty of Science, Palacky University in Olomouc, 17. listopadu 1192/12, 771 46, Olomouc, Czech Republic. $7 gn_A_00001310
- 700 1_
- $a Kalina, Petr $u Department of Chemistry of Natural Compounds, Faculty of Science, University of Chemistry and Technology, Technicka 5, 166 28, Prague, Czech Republic.
- 700 1_
- $a Drašar, Pavel $u Department of Chemistry of Natural Compounds, Faculty of Science, University of Chemistry and Technology, Technicka 5, 166 28, Prague, Czech Republic.
- 700 1_
- $a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
- 700 1_
- $a Gurska, Sona $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
- 700 1_
- $a Rehulka, Jiri $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
- 700 1_
- $a Urban, Milan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic. $7 xx0117688
- 700 1_
- $a Sarek, Jan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00, Olomouc, Czech Republic.
- 773 0_
- $w MED00173270 $t ChemMedChem $x 1860-7187 $g Roč. 12, č. 5 (2017), s. 390-398
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28084676 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20200728083832 $b ABA008
- 999 __
- $a ok $b bmc $g 1239044 $s 984276
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 5 $d 390-398 $e 20170127 $i 1860-7187 $m ChemMedChem $n ChemMedChem $x MED00173270
- LZP __
- $a Pubmed-20170720